Sutro Biopharma

Sutro Biopharma

Biotechnology
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

$191.3M

Market Cap • 10/20/2026

2003

(23 years)

Founded

2018

(8 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

0,2

P/S

4,2

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

57,4

EPS

—

Market Cap

Market Cap

191,3M

EV

37,8M

EV/Revenue

0,8

EV/EBITDA

-0,3

EV/EBIT

-0,3

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-53,7%

Total Yield

-53,7%

Payout

0%

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

316,7%

Capex/Revenue

1%

Capex/D&A

7,4%

Capex/OCF

-0,3%

SBC/OCF

—

% PPE

8,7%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

-7,9%

CAGR Op. Income 5Y

17,8%

CAGR Net Income 5Y

18%

CAGR EPS 5Y

-4,9%

CAGR OCF 5Y

49,5%

Leverage

N.D./EBITDA

1,1

Debt/Equity

0%

Current Ratio

3,3

Quick Ratio

3,2

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium